Xylazine is an alpha-2 adrenergic receptor agonist, approved by the U.S. Food and
Drug Administration (FDA) as a sedative and analgesic in veterinary medicine. In 1962,
xylazine was first synthesized by Bayer Pharmaceutics as a potential analgesic,
sleeping aid, and anesthetic for human use. However, clinical trials were terminated
prematurely due to severe hypotension and clinical nervous system (CNS) depression
induced in clinical participants.
Please read Dr. Allen's complete article beginning on Page 4